Clinical trials: Hepatic Neoplasm
Uveal Melanoma, Hepatic Metastases
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy.
- Trial name
- NCT02913417
- Testing
- SIR-Spheres® Yttrium 90, ipilimumab, nivolumab
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- David Minor, MD
Carcinoma, Hepatocellular
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
This is a study to investigate the potential clinical benefit of refametinib in patients with unresectable or metastatic HCC carrying a RAS mutation. The study will be conducted in 2 stages.
- Trial name
- NCT01915589
- Testing
- Refametinib (BAY86-9766)
- Where
- 58 sites in United States, Austria and 15 more
- Volunteers
- 16 people
- Sponsor
- Bayer
Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
The goal of this clinical trial is to help learn about the safety and feasibility of hepatic artery infusion chemotherapy for those who have colorectal liver metastases, both resectable and unresectable, or unresectable…
- Trial name
- NCT07201519
- Testing
- Hepatic Artery Infusion Pump (HAIP), Standard Treatment, Community Treatment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Michael J Cavnar, MD
Hepatocellular Carcinoma
The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma
Hepatocellular carcinoma is one of the most common solid malignant tumors. The prognosis of unresectable hepatocellular carcinoma is very poor.
- Trial name
- NCT05760430
- Testing
- PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Oligometastatic Disease, Liver Metastases
Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases
If an abbreviated hepatobiliary phase (HBP) protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal…
- Conditions
- Oligometastatic Disease, Liver Metastases, Colorectal Cancer
- Trial name
- NCT04973007
- Testing
- Gadoxetate disodium, Gadobenate dimeglumine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Chronic Hepatitis b
A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and Cirrhosis
This was a retrospective observational cohort study. The patients with chronic hepatitis B and cirrhosis who were treated with antiviral therapy in the Second Department of Liver Disease, Beijing Ditan Hospital, Capital Medical…
- Trial name
- NCT04301908
- Testing
- interferon
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Ditan Hospital
Hepatocellular Carcinoma
Ablation Combined With PD-1 in HCC: Phase II Study
This is a Phase 2, single arm, single center study designed to evaluate the safety and tolerability of radiofrequency or microwave ablation combined with PD-1 monoclonal antibody in patients with hepatocellular carcinoma(HCC)…
- Trial name
- NCT04652440
- Testing
- PD-1 monoclonal antibody, Radiofequencey or microwave ablation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
The most frequently used products in CHE are doxorubicin (36%), cisplatin (31%), and epirubicin (12%). But until recently, there were no obvious reasons to use one product over another.
- Trial name
- IDASPHERE II (NCT02185768)
- Testing
- idarubicin, Dc- Beads 300-500µm
- Where
- 7 sites in France
- Volunteers
- 46 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Hepatocellular Carcinoma
Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)
This Phase I/II trial will evaluate the safety and activity of chemo-radiotherapy comprising a regimen of Sorafenib chemotherapy plus SIR-Spheres yttrium-90 microspheres (chemo-radiotherapy, also known as "chemo-SIRT"), for…
- Trial name
- NCT00712790
- Testing
- Sorafenib, SIR-Spheres
- Where
- 5 sites in Burma, Malaysia and 2 more
- Volunteers
- 35 people
- Sponsor
- Singapore Clinical Research Institute
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer
- Trial name
- NCT00085410
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Cancer of Liver, Cancer of Pancreas
Effects of Dexmedetomidine During IRE Procedures for Solid Tumours
The purpose of the study is to evaluate effects of dexmedetomidine on anaesthesia during IRE procedures for solid tumours
- Trial name
- NCT02044224
- Testing
- Dexmedetomidine
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Uppsala University Hospital
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Liver Cirrhosis
FDGal PET/CT to Detect Hepatocellular Carcinoma
Liver cancer is one of the leading causes of cancer death among Asian men. If diagnosed early the disease is treatable with surgery. Current conventional imaging modalities have limitations to early detection.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Liver Disease
- Trial name
- NCT02899325
- Testing
- Diagnostic PET/CT scans
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Hepatocellular Carcinoma
AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)
This study aims to prospectively validate a retrospective cohort-derived AI-based multimodal model and explore tumor heterogeneity and the immune microenvironment to guide TACE combined with immunotherapy and targeted therapy in…
- Trial name
- NCT07584317
- Testing
- Artificial Intelligence
- Volunteers
- 1,170 people
- Sponsor
- Gao-jun Teng
Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma
Unsatisfactory immediate outcomes of Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in surgery of cholangiocarcinoma suggested that patients with biliary cancer should not be treated by ALPPS.
- Trial name
- NCT03320980
- Testing
- RALPPS, portal vein embolization + major liver resection
- Volunteers
- 30 people
- Sponsor
- Moscow Clinical Scientific Center
Hepatocellular Carcinoma
Effect of Nutritional Indices on the Prognosis of HCC Patients
Primary liver cancer has recently ranked among the leading causes of cancer death, with hepatocellular carcinoma (HCC) accounting for 75%-85% of these cases.
- Trial name
- NCT05635279
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Juan Kang
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Advanced Solid Tumor, Hepatocellular Carcinoma
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer.
- Trial name
- NCT06005740
- Testing
- TORL-4-500
- Where
- 10 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Hepatocellular Carcinoma
Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
To evaluate the efficacy and safety of lenvatinib, tislelizumab combined with RALOX regimen HAIC in advanced hepatocellular carcinoma.
- Trial name
- NCT05954897
- Testing
- Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Guangdong Provincial People's Hospital